Replies to post #337740 on Amarin Corp Plc (AMRN)

[Lrich]

So you want a buyout, never?

In biotechs, for smaller bios, a 200% premium isn't wildly uncommon. At this point (thanks JT you moron) Amarin is "small"

What I don't get is, we have people like you saying "I don't want a buyout until the stock touches X" but you aren't out here raising hell and chewing on management via emails, phone calls, carrier pigeon, etc to get them to shape up and get us there.

Lastly, I'd rather take 10 in May than maybe 20 in 2024.

[ralphey]

There are rare buyouts ( usually smaller biotech ) at 3x but very rare the average is about 100%
https://www.evaluate.com/vantage/articles/news/snippets/biotech-deal-premiums-still-punchy

Over the odds? Biggest biopharma premiums paid since 2015
Acquirer Target (year) Deal value ($bn) 30-day premium
Sanofi Synthorx (2019) 2.5 282%
Allergan Vitae (2016) 0.6 173%
Roche Spark (2019) 4.8 143%
Nestlé Aimmune (2020) 2.6 141%
Alexion Portola (2020) 1.4 139%